Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel
- 25 February 2005
- journal article
- clinical trial
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 64 (3) , 369-372
- https://doi.org/10.1002/ccd.20257
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devicesAmerican Heart Journal, 2004
- A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the Evaluating Enoxaparin Clotting Times (ELECT) StudyJournal of the American College of Cardiology, 2003
- Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary InterventionJAMA, 2003
- Vascular closure devices in patients treated with anticoagulation and iib/iiia receptor inhibitors during percutaneous revascularizationJournal of the American College of Cardiology, 2002
- Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockadeThe American Journal of Cardiology, 2000
- Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without EptifibatideJournal of the American College of Cardiology, 1998
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988